Quince Therapeutics, Inc. 8-K

What Happened
Quince Therapeutics, Inc. announced it paid EUR 4,800,000 (approximately $5.5 million) on March 27, 2026 to the European Investment Bank (EIB) on behalf of its subsidiary, Quince Therapeutics S.p.A., in full settlement of outstanding obligations under a July 24, 2020 finance contract and related guarantee agreement. As a result of the payment, the company and the subsidiary’s obligations under those finance documents were deemed satisfied. The company issued a press release about the settlement on March 30, 2026 (furnished as Exhibit 99.1 in the 8-K).

Key Details

• Payment date: March 27, 2026.
• Amount paid: EUR 4,800,000 (≈ $5.5 million).
• Parties: Quince Therapeutics, Inc. (payer/guarantor), Quince Therapeutics S.p.A. (borrower), European Investment Bank (lender).
• Outcome: Finance Contract (originally dated July 24, 2020) and related Guarantee Agreement obligations were satisfied and terminated.

Why It Matters
This action removes the outstanding obligations under the specified EIB finance documents, eliminating that liability for the company and its Italian subsidiary. It also involved a cash outflow of roughly $5.5 million, which is a concrete use of corporate funds investors should note when assessing near-term liquidity. The company made the information public via a press release under Regulation FD, so shareholders and the market have been informed of the settlement.